Goldbach-Mansky, Raphaela
- National Institute of Allergy and Infectious Diseases (no department on record)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #2,349
- Rising Star
- Sustained Excellence
- Long-Funded
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2007 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2023
Linked Award Amount
$2.6M
Full award amounts, FY2023
Award Records
2
Records listing this PI
Award-Linked Rank
#2,349
By linked amount among FY2023 PIs
Earliest Year Loaded
2007
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Goldbach-Mansky, Raphaela as a PI. Multi-PI records show the full award amount for context.
- 1ZIAAI001220-07ZIAContact PIPathogenesis, and Outcome of Autoinflammatory Diseases, NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still's-like Diseases, and other Undifferentiated Autoinflammatory Diseases$2.6Maward amount
- 1ZIAAI001303-04ZIAContact PILongitudinal IFN signature response and cytokine profiling in patients with severe COVID infections$10.7Kaward amount
Award organization
Organizations that administered FY2023 awards listing Goldbach-Mansky, Raphaela as a PI.
FY2023 award administered by National Institute of Allergy and Infectious Diseases ().
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2007First NIH AwardNational Institute of Allergy and Infectious Diseases
- 2007$500K Cumulative Funding
- 2008$1M Cumulative Funding
- 2008$2M Cumulative Funding
- 2008Entered Top 50% NationallyRanked #2932
- 2008Entered Top 25% NationallyRanked #2932
- 2011$5M Cumulative Funding
- 2015$10M Cumulative Funding
- 2018Entered Top 10% NationallyRanked #1492
- 2023$25M Cumulative Funding